Protagonist Therapeutics (NASDAQ:PTGX) Reaches New 12-Month High at $26.08

Protagonist Therapeutics, Inc. (NASDAQ:PTGX – Get Rating) hit a new 52-week high on Friday . The company traded as high as $26.08 and last traded at $25.72, with a volume of 136010 shares changing hands. The stock had previously closed at $23.60.

Wall Street Analyst Weigh In

Several analysts have issued reports on PTGX shares. StockNews.com downgraded Protagonist Therapeutics from a “hold” rating to a “sell” rating in a report on Friday, March 24th. HC Wainwright boosted their price objective on Protagonist Therapeutics from $33.00 to $38.00 and gave the stock a “buy” rating in a report on Thursday, March 16th. Finally, JMP Securities cut their price objective on Protagonist Therapeutics from $31.00 to $28.00 and set a “market outperform” rating on the stock in a report on Thursday, March 16th.

Protagonist Therapeutics Stock Up 5.1 %

The stock has a market cap of $1.28 billion, a P/E ratio of -9.54 and a beta of 1.96. The business has a 50-day simple moving average of $21.47 and a 200-day simple moving average of $14.49.

Institutional Investors Weigh In On Protagonist Therapeutics

Hedge funds have recently modified their holdings of the business. Legal & General Group Plc lifted its position in Protagonist Therapeutics by 8.4% in the fourth quarter. Legal & General Group Plc now owns 14,408 shares of the company’s stock worth $157,000 after purchasing an additional 1,118 shares during the period. Bank of New York Mellon Corp lifted its position in Protagonist Therapeutics by 0.9% in the first quarter. Bank of New York Mellon Corp now owns 139,769 shares of the company’s stock worth $3,310,000 after purchasing an additional 1,275 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank lifted its position in Protagonist Therapeutics by 18.6% in the fourth quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 8,536 shares of the company’s stock worth $93,000 after purchasing an additional 1,337 shares during the period. Allspring Global Investments Holdings LLC lifted its position in Protagonist Therapeutics by 13.3% in the third quarter. Allspring Global Investments Holdings LLC now owns 11,687 shares of the company’s stock worth $98,000 after purchasing an additional 1,375 shares during the period. Finally, Principal Financial Group Inc. lifted its position in Protagonist Therapeutics by 13.4% in the fourth quarter. Principal Financial Group Inc. now owns 11,738 shares of the company’s stock worth $128,000 after purchasing an additional 1,389 shares during the period. 91.51% of the stock is owned by institutional investors.

Protagonist Therapeutics Company Profile

(Get Rating)

Protagonist Therapeutics, Inc a clinical-stage biopharmaceutical company, which engages in discovering and developing peptide-based therapeutic drugs to address unmet medical needs. Its product pipeline includes PTG-300, PTG-200, and PN-943. The company was founded by Mark L. Smythe on August 22, 2006 and is headquartered in Newark, CA.